Navigation Links
Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
Date:11/8/2012

SOUTH SAN FRANCISCO, Calif., Nov. 8, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 2012 Global Healthcare Conference in London on Thursday, November 15th at 1:40 p.m. GMT.

To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.

Contact: Ryan Maynard   
Phone: 650.624.1284   
Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Rigel Announces Third Quarter 2012 Financial Results
2. Rigel to Present at UBS Global Life Sciences Conference
3. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
4. Rigel Announces Second Quarter 2012 Financial Results
5. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
6. Rigel Announces First Quarter 2012 Financial Results
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Isis Pharmaceuticals To Present At The 2012 Credit Suisse Healthcare Conference
9. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
10. VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings
11. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016   ... sur le trimestre, soutenu par une croissance de ... Croissance de +16% des ventes aux hôpitaux et ... Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de ... son chiffre d,affaires pour le premier trimestre clos ...
(Date:4/27/2016)... , April 27, 2016   Zillion ... its digital health technology platform, which specializes in ... programs into scalable digital products, Zillion enables companies ... and empower consumers to take control of their ... live video conferencing – including one-to-one, group and ...
(Date:4/27/2016)... , April 27, 2016 ... of the  "Global Anesthesia Disposables Market 2016-2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ,The global anesthesia disposables ... CAGR of 4.03% during the period 2016-2020.  ... major threat to patients, safety. Organizations like ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... A ... use of the HyProCure sinus tarsi implant. ( http://www.cbc.ca/news/canada/ottawa/banned-quebec-dentist-pierre-dupont-working-as-chiropodist-in-ottawa-1.3515494 ) The ... minimally invasive procedure performed, when indicated, to correct the partial displacement of ...
(Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding its ... following programs will be expanding due to high demand: Master of Business Administration (MBA), ... begin this summer. , School of Business Graduate Program Chair Dr. Ray ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... . Dr. Bernie Siegel, author of a plethora of essential books-to-read for ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
Breaking Medicine News(10 mins):